No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study - Concepedia

Concepedia

Publication | Closed Access

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

54

Citations

26

References

2018

Year

Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Manuela Matta, Lucia Moiola, Luigina Musu, Paola Perini, Carlo Avolio,

Journal of Neurology

Disease ProgressionNeurological DisorderClinical TrialsDisability ImprovementRehabilitationNeurologyMultiple SclerosisDisease ActivityMedicine

References

	Year	Citations

Page 1

Page 1